NEVRO CORP.

Manufacturer adverse-event records for NEVRO CORP. come from the U.S. Food & Drug Administration (FDA) MAUDE database via openFDA, refreshed March 2026 - see our methodology. Not medical advice.

FDA MAUDE device safety record · 2017–2026 · thin-book · elevated Death-code · injury-heavy

Death-code intensity

NEVRO CORP. carries an elevated Death-code share

Death-coded event_type rows are 930 of 5,707 (16.30% · elevated tercile among 443 manufacturers). Absolute volume is thin-book.

What the Death-code reading shows for NEVRO CORP.

The standout signal for NEVRO CORP. is Death-code intensity: 16.30% of 5,707 reports (elevated tercile), while absolute volume is thin-book.

As a thinner-book manufacturer, a handful of device families can swing the totals; open the device table rather than reading the company headline alone. Event_type counts are not the same population as Patient Outcomes.

Reports span 2 device types, led in this extract by Injury at 4,557 (79.8% of event_type total). Peak single-year volume reaches 1,173 reports across 10 years. These are raw FDA submissions, not adjudicated findings. Snapshot . Verify current communications on the FDA MDR page.

5,707
Total Reports
930
Event-type Death
4,557
Injury Reports
2
Device Types

Event Types

Injury 4,557 (79.8%)
Death 930 (16.3%)
Malfunction 217 (3.8%)
Other 2 (0.0%)
1 (0.0%)

Patient Outcomes

FDA patient-outcome codes (separate from event_type). Percentages use this chart's row total.

Other 2,114 (30.5%)
Required Intervention 1,802 (26.0%)
Death 930 (13.4%)
Hospitalization 611 (8.8%)
R 583 (8.4%)
H 510 (7.4%)
214 (3.1%)
O 93 (1.3%)
Disability 31 (0.4%)
S 25 (0.4%)
D 9 (0.1%)
L 9 (0.1%)
Life Threatening 4 (0.1%)
C 1 (0.0%)

Yearly Trend

17
2017: 121
18
2018: 419
19
2019: 517
20
2020: 427
21
2021: 579
22
2022: 618
23
2023: 793
24
2024: 1,173
25
2025: 976
26
2026: 84